Brief: Zealand Pharma Q1 EBIT Loss DKK 539 Mln
07/05/2026 06:13
May 7 (Reuters) - Zealand Pharma A/S ZELA.CO: Q1 REVENUE DKK 34 MILLION Q1 EBIT DKK LOSS 539 MILLION VERSUS IBES ESTIMATE LOSS DKK 672.37 MILLION 2026 OUTLOOK: UNCHANGED 2026 OUTLOOK: RECOGNISES USD 700 MILLION / DKK 4.5 BILLION AS COLLABORATION REVENUE IN Q2 OF 2026 Source text: ID:nGNE7xp7g4 Further company coverage: ZELA.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)